Drugs / M802
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04501770 | Sep 2018 → May 2022 | — | Wuhan YZY Biopharma Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-09-02 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - RECOMBINANT ANTI-HER2 AND ANTI-CD3 HUMANIZED BISPECIFIC ANTIBODY FOR INJECTION WAS GRANTED CLINICAL TRIAL APPROVAL BY U.S. FDA irasia.com ↗
M802) self-developed by Wuhan YZY Biopharma Co., Ltd.* ʮ̡ (“YZY Biopharma”), a non-wholly owned subsidiary of the Group, was granted clinical trial approval by the U.S. Food and Drug Administration (U.S. FDA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-09-02 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - RECOMBINANT ANTI-HER2 AND ANTI-CD3 HUMANIZED BISPECIFIC ANTIBODY FOR INJECTION WAS GRANTED CLINICAL TRIAL APPROVAL BY U.S. FDA irasia.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04501770 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-HER2 and Anti-CD3 Humanized Bispecific Antibody (M802)” NCT04501770 ↗ |
| Route | Intravenous | “M802 via intravenous infusion” NCT04501770 ↗ |